Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused a worldwide severe coronavirus disease 2019(COVID-19)pandemic since December 2019.There is a great demand for effective therapies for the preventio...Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused a worldwide severe coronavirus disease 2019(COVID-19)pandemic since December 2019.There is a great demand for effective therapies for the prevention and treatment of COVID-19.Developing therapeutic neutralizing antibodies(NAbs),which could block viral infection,is such a promising approach,as NAbs have been successfully applied to the treatment of other viral infections.The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs,and many of which are now actively tested in clinical trials.Here,we review the approaches applied for SARS-CoV-2 NAb development,and discuss the emerging technologies underlining the antibody discovery.We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features.展开更多
基金Work in the authors'labs was supported by the National Key R&D Program of China(2017YFA0506700)the National Natural Science Foundation of China(81622022 and 31970880 to F.-L.M.,31722020,81671634,and 8186113801A to L.-S.Y.)+1 种基金Shanghai Jiao Tong University COVID-19 grant to L.-S.Y.Shanghai Science and Technology Committee(20490760200)to F.-L.M.
文摘Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused a worldwide severe coronavirus disease 2019(COVID-19)pandemic since December 2019.There is a great demand for effective therapies for the prevention and treatment of COVID-19.Developing therapeutic neutralizing antibodies(NAbs),which could block viral infection,is such a promising approach,as NAbs have been successfully applied to the treatment of other viral infections.The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs,and many of which are now actively tested in clinical trials.Here,we review the approaches applied for SARS-CoV-2 NAb development,and discuss the emerging technologies underlining the antibody discovery.We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features.
